A randomized, open-label study to compare the effect of PEGASYS [peginterferon alfa-2a] monotherapy and PEGASYS + ribavirin combination therapy on treatment response in patients with chronic hepatitis D
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2010
At a glance
- Drugs Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis D
- Focus Therapeutic Use
- Sponsors Roche
- 18 Nov 2009 Status changed from active, no longer recruiting to completed as Roche record.
- 21 Feb 2008 New trial record.